The Preclinical Discovery and Development of Depemokimab for Severe Eosinophilic Asthma
DOI:
文献链接:
其他信息:
M Cazzola, V Patella, R Pagliaro, A Bianco…
Pulmonary …, 2026
Elsevier
Severe eosinophilic asthma is driven by interleukin (IL)-5-mediated type 2 inflammation and frequently requires long-term biologic therapy. Depemokimab was designed to achieve sustained IL-5 neutralization with a twice-yearly dosing schedule, addressing key unmet needs related to treatment burden and adherence. This review summarizes the molecular design, preclinical pharmacology, model-informed drug development (MIDD) strategy, and Phase I-III clinical trial program, and regulatory approvals of depemokimab in asthma and …

